Gastrointestinal Tumors of the Colon and Rectum

ABSTRACT

Gastrointestinal stromal tumors (GISTs) of the colon and rectum are the most common mesenchymal tumors of the gastrointestinal tract. GISTs of the colon and rectum constitute ~5% of all cases. Although colorectal GISTs can be small and found incidentally, the majority appear to be high risk and carry a significant likelihood of recurrent and metastatic disease. Surgery remains the mainstay of treatment for primary disease. There is now considerable interest in GISTs because they can be treated effectively with targeted molecular therapies, specifically tyrosine kinase inhibitors (TKIs), such as imatinib mesylate and sunitinib malate. GISTs are best treated by a multidisciplinary team comprised of the surgeon, medical oncologist, pathologist, and radiologist in the initial evaluation, management, and in continued follow-up. Increasing the number of resectable cases through pharmacologic debulking, optimizing the timing of surgery and organ preservation, reducing recurrence and surgical morbidity, prolonging survival, and possibly enhancing response to imatinib through surgical cytoreduction are all potential benefits of multidisciplinary management.

KEYWORDS

Colorectal/rectal GIST - prognostic factors - neoadjuvant/adjuvant imatinib

REFERENCES

• 1 Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis.  Arch Pathol Lab Med. 2006;  130 (10) 1466-1478
• 2 Miettinen M, Furlong M, Sarlomo-Rikala M, Burke A, Sobin L H, Lasota J. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus: a clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases.  Am J Surg Pathol. 2001;  25 (9) 1121-1133
• 3 Miettinen M, Sarlomo-Rikala M, Sobin L H, Lasota J. Gastrointestinal stromal tumors and leiomyosarcomas in the colon: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases.  Am J Surg Pathol. 2000;  24 (10) 1339-1352
• 4 Robinson T L, Sircar K, Hewlett B R, Chorneyko K, Riddell R H, Huizinga J D. Gastrointestinal stromal tumors may originate from a subset of CD34-positive interstitial cells of Cajal.  Am J Pathol. 2000;  156 (4) 1157-1163
• 5 Du C Y, Shi Y Q, Zhou Y, Fu H, Zhao G. The analysis of status and clinical implication of KIT and PDGFRA mutations in gastrointestinal stromal tumor (GIST).  J Surg Oncol. 2008;  98 (3) 175-178
• 6 Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.  Histopathology. 2008;  53 (3) 245-266
• 7 Lasota J, Jasinski M, Sarlomo-Rikala M, Miettinen M. Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas.  Am J Pathol. 1999;  154 (1) 53-60
• 8 Andersson J, Bümming P, Meis-Kindblom J M et al.. Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis.  Gastroenterology. 2006;  130 (6) 1573-1581
• 9 Rubin B P, Singer S, Tsao C et al.. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.  Cancer Res. 2001;  61 (22) 8118-8121
• 10 Corless C L, McGreevey L, Haley A, Town A, Heinrich M C. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size.  Am J Pathol. 2002;  160 (5) 1567-1572
• 11 Lasota J, Miettinen M. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs).  Semin Diagn Pathol. 2006;  23 (2) 91-102
• 12 Hou Y Y, Grabellus F, Weber F et al.. Impact of KIT and PDGFRA gene mutations on prognosis of patients with gastrointestinal stromal tumors after complete primary tumor resection.  J Gastrointest Surg. 2009;  13 (9) 1583-1592
• 13 Hassan I, You Y N, Dozois E J et al.. Clinical, pathologic, and immunohistochemical characteristics of gastrointestinal stromal tumors of the colon and rectum: implications for surgical management and adjuvant therapies.  Dis Colon Rectum. 2006;  49 (5) 609-615
• 14 Changchien C R, Wu M C, Tasi W S et al.. Evaluation of prognosis for malignant rectal gastrointestinal stromal tumor by clinical parameters and immunohistochemical staining.  Dis Colon Rectum. 2004;  47 (11) 1922-1929
• 15 Hirota S, Ohashi A, Nishida T et al.. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors.  Gastroenterology. 2003;  125 (3) 660-667
• 16 Demetri G D, von Mehren M, Antonescu C R et al.. NCCN task force report: update on the management of patients with gastrointestinal stromal tumors.  J Natl Compr Canc Netw. 2010;  8 (Suppl 2) S1-S41, quiz S42–S44
• 17 Levy A D, Remotti H E, Thompson W M, Sobin L H, Miettinen M. Anorectal gastrointestinal stromal tumors: CT and MR imaging features with clinical and pathologic correlation.  AJR Am J Roentgenol. 2003;  180 (6) 1607-1612
• 18 Ji F, Wang Z W, Wang L J, Ning J W, Xu G Q. Clinicopathological characteristics of gastrointestinal mesenchymal tumors and diagnostic value of endoscopic ultrasonography.  J Gastroenterol Hepatol. 2008;  23 (8 Pt 2) e318-e324
• 19 van den Berg J C, van Heesewijk J P, van Es H W. Malignant stromal tumour of the rectum: findings at endorectal ultrasound and MRI.  Br J Radiol. 2000;  73 (873) 1010-1012
• 20 Ha C Y, Shah R, Chen J, Azar R R, Edmundowicz S A, Early D S. Diagnosis and management of GI stromal tumors by EUS-FNA: a survey of opinions and practices of endosonographers.  Gastrointest Endosc. 2009;  69 (6) 1039-1044, e1
• 21 Sepe P S, Brugge W R. A guide for the diagnosis and management of gastrointestinal stromal cell tumors.  Nat Rev Gastroenterol Hepatol. 2009;  6 (6) 363-371
• 22 Akahoshi K, Sumida Y, Matsui N et al.. Preoperative diagnosis of gastrointestinal stromal tumor by endoscopic ultrasound-guided fine needle aspiration.  World J Gastroenterol. 2011;  13 (14) 2077-2082
• 23 Elliott D D, Fanning C V, Caraway N P. The utility of fine-needle aspiration in the diagnosis of gastrointestinal stromal tumors: a cytomorphologic and immunohistochemical analysis with emphasis on malignant tumors.  Cancer. 2006;  108 (1) 49-55
• 24 Sarlomo-Rikala M, Kovatich A J, Barusevicius A, Miettinen M. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34.  Mod Pathol. 1998;  11 (8) 728-734
• 25 Miettinen M, Sobin L H, Sarlomo-Rikala M. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT).  Mod Pathol. 2000;  13 (10) 1134-1142
• 26 Miettinen M, Lasota J. Gastrointestinal stromal tumors (GISTs): definition, occurrence, pathology, differential diagnosis and molecular genetics.  Pol J Pathol. 2003;  54 (1) 3-24
• 27 Katz S C, DeMatteo R P. Gastrointestinal stromal tumors and leiomyosarcomas.  J Surg Oncol. 2008;  97 (4) 350-359
• 28 Yamaguchi U, Hasegawa T, Masuda T et al.. Differential diagnosis of gastrointestinal stromal tumor and other spindle cell tumors in the gastrointestinal tract based on immunohistochemical analysis.  Virchows Arch. 2004;  445 (2) 142-150
• 29 Fletcher C D, Berman J J, Corless C et al.. Diagnosis of gastrointestinal stromal tumors: a consensus approach.  Hum Pathol. 2002;  33 (5) 459-465
• 30 Miettinen M, Sobin L H, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up.  Am J Surg Pathol. 2005;  29 (1) 52-68
• 31 Miettinen M, Makhlouf H, Sobin L H, Lasota J. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up.  Am J Surg Pathol. 2006;  30 (4) 477-489
• 32 Miettinen M, Lasota J. Gastrointestinal stromal tumors—definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis.  Virchows Arch. 2001;  438 (1) 1-12
• 32a Agaimy A. Gastrointestinal stromal tumors (GIST) from risk stratification systems to the new TNM proposal: more questions than answers? A review emphasizing the need for a standardized GIST reporting.  Int J Clin Exp Pathol. 2010;  3 (5) 461-471
• 33 Martín J, Poveda A, Llombart-Bosch A Spanish Group for Sarcoma Research et al. Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS).  J Clin Oncol. 2005;  23 (25) 6190-6198
• 34 Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites.  Semin Diagn Pathol. 2006;  23 (2) 70-83
• 35 Dematteo R P, Gold J S, Saran L et al.. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST).  Cancer. 2008;  112 (3) 608-615
• 36 Gold J S, Gönen M, Gutiérrez A et al.. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis.  Lancet Oncol. 2009;  10 (11) 1045-1052
• 37 Tsai M C, Lin J W, Lin S E, Chen H H, Lee C M, Hu T H. Prognostic analysis of rectal stromal tumors by reference of National Institutes of Health risk categories and immunohistochemical studies.  Dis Colon Rectum. 2008;  51 (10) 1535-1543
• 38 Hu T H, Tai M H, Chuah S K et al.. Elevated p21 expression is associated with poor prognosis of rectal stromal tumors after resection.  J Surg Oncol. 2008;  98 (2) 117-123
• 39 Hu T H, Lin J W, Chen H H, Liu L F, Chuah S K, Tai M H. The expression and prognostic role of hepatoma-derived growth factor in colorectal stromal tumors.  Dis Colon Rectum. 2009;  52 (2) 319-326
• 40 Tai W C, Chuah S K, Lin J W et al.. Colorectal mesenchymal tumors - from smooth muscle tumors to stromal tumors.  Oncol Rep. 2008;  20 (5) 1157-1164
• 41 Dong C, Jun-Hui C, Xiao-Jun Y et al.. Gastrointestinal stromal tumors of the rectum: clinical, pathologic, immunohistochemical characteristics and prognostic analysis.  Scand J Gastroenterol. 2007;  42 (10) 1221-1229
• 42 Weber A G, Jovenin N, Lubrano D et al.. Outcome after surgical treatment of gastrointestinal stromal tumors.  Gastroenterol Clin Biol. 2007;  31 (6-7) 579-584
• 43 Hohenberger P, Ronellenfitsch U, Oladeji O et al.. Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour.  Br J Surg. 2010;  97 (12) 1854-1859
• 44 Chen C W, Wu C C, Hsiao C W et al.. Surgical management and clinical outcome of gastrointestinal stromal tumor of the colon and rectum.  Z Gastroenterol. 2008;  46 (8) 760-765
• 45 Li J C, Ng S S, Lo A W, Lee J F, Yiu R Y, Leung K L. Outcome of radical excision of anorectal gastrointestinal stromal tumors in Hong Kong Chinese patients.  Indian J Gastroenterol. 2007;  26 (1) 33-35
• 46 Hellan M, Maker V K. Transvaginal excision of a large rectal stromal tumor: an alternative.  Am J Surg. 2006;  191 (1) 121-123
• 47 DeMatteo R P, Lewis J J, Leung D, Mudan S S, Woodruff J M, Brennan M F. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.  Ann Surg. 2000;  231 (1) 51-58
• 48 Nishimura J, Nakajima K, Omori T et al.. Surgical strategy for gastric gastrointestinal stromal tumors: laparoscopic vs. open resection.  Surg Endosc. 2007;  21 (6) 875-878
• 49 Chang S C, Ke T W, Chiang H C, Wu C, Chen W T. Laparoscopic excision is an alternative method for rectal gastrointestinal stromal tumor.  Surg Laparosc Endosc Percutan Tech. 2010;  20 (4) 284-287
• 50 Nakamura T, Ihara A, Mitomi H et al.. Gastrointestinal stromal tumor of the rectum resected by laparoscopic surgery: report of a case.  Surg Today. 2007;  37 (11) 1004-1008
• 51 Edmonson J H, Marks R S, Buckner J C, Mahoney M R. Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas.  Cancer Invest. 2002;  20 (5-6) 605-612
• 52 Artinyan A, Kim J, Soriano P, Chow W, Bhatia S, Ellenhorn J D. Metastatic gastrointestinal stromal tumors in the era of imatinib: improved survival and elimination of socioeconomic survival disparities.  Cancer Epidemiol Biomarkers Prev. 2008;  17 (8) 2194-2201
• 53 Demetri G D, von Mehren M, Blanke C D et al.. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.  N Engl J Med. 2002;  347 (7) 472-480
• 54 Dagher R, Cohen M, Williams G et al.. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.  Clin Cancer Res. 2002;  8 (10) 3034-3038
• 55 Demetri G D, van Oosterom A T, Garrett C R et al.. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.  Lancet. 2006;  368 (9544) 1329-1338
• 56 Demetri G D, Huang X, Garrett C R et al.. Novel statistical analysis of long-term survival to account for crossover in a phase III trial of sunitinib (SU) vs. placebo (PL) in advanced GIST afterimatinib (IM) failure.  [abstract] J Clin Oncol. 2008;  26 (Suppl 1) A10524
• 57 Hassan I, You Y N, Shyyan R et al.. Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis.  Ann Surg Oncol. 2008;  15 (1) 52-59
• 58 DeMatteo R P, Owzar K, Antonescu C R et al.. Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: the U.S. Intergroup phase II trial ACOSOG Z9000 [abstract 8].  Abstract presented at: The 2008 ASCO Gastrointestinal Cancers Symposium; January 25–27, 2008; Orlando, FL.
• 59 DeMatteo R, Owzar K, Maki R et al.. Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001 [abstract 10079].  Abstract presented at: The 43rd ASCO Annual Meeting; June 1–5, 2007; Chicago, IL.
• 60 Dematteo R P, Ballman K V, Antonescu C R American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.  Lancet. 2009;  373 (9669) 1097-1104
• 61 Antonescu C R, Besmer P, Guo T et al.. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.  Clin Cancer Res. 2005;  11 (11) 4182-4190
• 62 Heinrich M C, Corless C L, Blanke C D et al.. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.  J Clin Oncol. 2006;  24 (29) 4764-4774
• 63 Eisenberg B L, Harris J, Blanke C D et al.. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665.  J Surg Oncol. 2009;  99 (1) 42-47
• 64 McAuliffe J C, Hunt K K, Lazar A J et al.. A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis.  Ann Surg Oncol. 2009;  16 (4) 910-919
• 65 Machlenkin S, Pinsk I, Tulchinsky H et al.. The effect of neoadjuvant imatinib therapy on rectal gastrointestinal stromal tumours outcome and survival.  Colorectal Dis. 2010;  doi:10.1111/j.1463-1318.2010.02442.x [Epub ahead of print]
• 66 Fiore M, Palassini E, Fumagalli E et al.. Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST).  Eur J Surg Oncol. 2009;  35 (7) 739-745
• 67 Wang J P, Wang T, Huang M J, Wang L, Kang L, Wu X J. The role of neoadjuvant imatinib mesylate therapy in sphincter-preserving procedures for anorectal gastrointestinal stromal tumor.  Am J Clin Oncol. 2011;  34 (3) 314-316
• 68 Sekoguchi S, Okuyama Y, Enoki Y et al.. [A case of rectal GIST treated with imatinib mesylate neoadjuvant therapy to preserve the anus].  Nippon Shokakibyo Gakkai Zasshi. 2009;  106 (12) 1751-1757
• 69 Hou Y Y, Zhou Y, Lu S H et al.. Imatinib mesylate neoadjuvant treatment for rectal malignant gastrointestinal stromal tumor.  World J Gastroenterol. 2009;  15 (15) 1910-1913
• 70 Mandalà M, Pezzica E, Tamborini E et al.. Neoadjuvant imatinib in a locally advanced gastrointestinal stromal tumour (GIST) of the rectum: a rare case of two GISTs within a family without a familial GIST syndrome.  Eur J Gastroenterol Hepatol. 2007;  19 (8) 711-713
• 71 de Azevedo C R, Paiva Jr T F, Rossi B M et al.. Pathologic complete response with neoadjuvant imatinib for locally advanced pelvic GIST.  Int J Clin Oncol. 2011;  16 (3) 279-283
• 72 Ciresa M, D'Angelillo R M, Ramella S et al.. Molecularly targeted therapy and radiotherapy in the management of localized gastrointestinal stromal tumor (GIST) of the rectum: a case report.  Tumori. 2009;  95 (2) 236-239
• 73 Bonvalot S, Eldweny H, Péchoux C L et al.. Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era.  Ann Surg Oncol. 2006;  13 (12) 1596-1603
• 74 Li J, Gong F J, Wu W A, Shen L. Adjuvant therapy with imatinib in gastrointestinal stromal tumor (GIST) patients with intermediate or high risk: analysis from a single-center contrast study.  [abstract]. J Clin Oncol. 2009;  27 (Suppl 1) A10556
• 75 Raut C P, Posner M, Desai J et al.. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors.  J Clin Oncol. 2006;  24 (15) 2325-2331
• 76 DeMatteo R P, Maki R G, Singer S, Gonen M, Brennan M F, Antonescu C R. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor.  Ann Surg. 2007;  245 (3) 347-352
• 77 Hamada M, Ozaki K, Horimi T et al.. Recurrent rectal GIST resected successfully after preoperative chemotherapy with imatinib mesylate.  Int J Clin Oncol. 2008;  13 (4) 355-360
• 78 Tsutsui M, Yoshino S, Sakamoto K, Oka M. [Long-term survival after surgery and adjuvant imatinib in a patient with rectal GIST, local recurrence, liver metastases and mediastinal pleural metastasis].  Gan To Kagaku Ryoho. 2009;  36 (12) 2351-2353